DRKS00007716
Completed
Not Applicable
Walter, S. (2017) Evaluation of a Palliative Care Training Program for Nurses - the ELNEC - Palliative Care Course Germany. Unpublished Masterthesis Albert-Ludwigs-Universität Freiburg
niversitätsklinikum Freiburg, Klinik für Palliativmedizin0 sites18 target enrollmentJanuary 29, 2015
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Participant of the ELNEC - Palliative Care Course Germany
- Sponsor
- niversitätsklinikum Freiburg, Klinik für Palliativmedizin
- Enrollment
- 18
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) ELNEC\-Trainer, who work in the akut care setting, home care or nursing and residential care homes
- •2\) ELNEC\-Trainer, who participate voluntary at narrative interviews
Exclusion Criteria
- •ELNEC\-Trainer, who refuse an interview
- •ELNEC\-Trainer, whose senior refuse that the employee participate
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients with major depressive disorderEUCTR2007-003159-36-FRsanofi-aventis recherche & développement675
Active, not recruiting
Not Applicable
An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients with major depressive disorderEUCTR2007-003159-36-SEsanofi-aventis recherche & développement615
Active, not recruiting
Not Applicable
An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients with major depressive disorderEUCTR2007-003159-36-FIsanofi-aventis recherche & développement615
Active, not recruiting
Not Applicable
An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study toEvaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as AdjunctiveTherapy in Adults With Major Depression Associated WithBipolar I DisorderMajor Depression Associated With Bipolar I DisorderMedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depressionEUCTR2007-007555-14-HUCephalon, Inc.240
Active, not recruiting
Not Applicable
An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study toEvaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as AdjunctiveTherapy in Adults With Major Depression Associated WithBipolar I DisorderMajor Depression Associated With Bipolar I DisorderMedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depressionEUCTR2007-007555-14-BGCephalon, Inc.240